Department of Dermatology, Centro Hospitalar do Porto, Porto, Portugal.
Instituto de Ciências Biomédicas Abel Salazar, University of Portugal, Porto, Portugal.
Am J Clin Dermatol. 2016 Apr;17(2):107-12. doi: 10.1007/s40257-015-0166-0.
Psoriasis is a chronic, immune-mediated inflammatory disorder associated with systemic inflammation and a significantly increased risk of cardiovascular disease. Common pathologic mechanisms are likely involved in the pathogenesis of psoriasis and atherosclerosis, including similar inflammatory cytokine profiles and proinflammatory cell types. The hypothesis that aggressive treatment of skin inflammation may decrease the risk of developing atherosclerosis and consequently cardiovascular disease is currently a focus of major attention. Interleukin (IL)-17 may be an important cytokine linking skin disease to vascular disease/inflammation. However, the role of IL-17 in atherosclerosis is still controversial, as IL-17 may exhibit pro-atherogenic or anti-atherogenic effects depending on the specific tissue, cellular, and immune context. Given the development of several IL-17 inhibitors, the investigation of IL-17 inhibition impact on cardiovascular outcome is extremely important.
银屑病是一种慢性、免疫介导的炎症性疾病，与全身炎症和心血管疾病风险显著增加有关。银屑病和动脉粥样硬化的发病机制可能涉及共同的病理机制，包括相似的炎症细胞因子谱和促炎细胞类型。目前，一个主要关注的假设是，积极治疗皮肤炎症可能降低发生动脉粥样硬化和心血管疾病的风险。白细胞介素（IL）-17 可能是将皮肤疾病与血管疾病/炎症联系起来的重要细胞因子。然而，IL-17 在动脉粥样硬化中的作用仍存在争议，因为 IL-17 可能根据特定的组织、细胞和免疫环境表现出促动脉粥样硬化或抗动脉粥样硬化的作用。鉴于几种 IL-17 抑制剂的开发，研究 IL-17 抑制对心血管结局的影响至关重要。
